Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Cancer Therapies02:49

Cancer Therapies

8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

170
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
170

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inpatient Outcomes of Pancreatic Cancer Surgery in Patients with Coronary Artery Disease.

Cancers·2026
Same author

Role of individualized intervention(s) on quality of life and adherence to adjuvant endocrine therapy in premenopausal women with early-stage breast cancer: MyCHOICE study.

Breast cancer research and treatment·2026
Same author

Racial and Ethnic Disparities in the Management and Outcomes of Acute Myocardial Infarction Complicated by Ventricular Arrhythmias.

Journal of clinical medicine·2026
Same author

Structured Exercise Program After Adjuvant Chemotherapy for Colon Cancer: A Cost-Utility Analysis of the CHALLENGE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Diabetes Mellitus and Survival Outcomes in Women With Early-Stage Triple-Negative Breast Cancer: A Multicentre Population-Based Cohort Study From Saskatchewan.

Canadian journal of diabetes·2026
Same author

From Gut to Globe: Endogenous Endophthalmitis as a Sentinel Sign of Polymicrobial Intra-Abdominal Infection.

Clinical case reports·2026
Same journal

Feasibility of Surgical Resection for Advanced Gallbladder Carcinoma Based on Preoperative Clinical T Stagings: A Multicenter Retrospective Analysis (SNOW-22-05).

Journal of hepato-biliary-pancreatic sciences·2026
Same journal

Histological Analysis of Cryopreserved Venous Allografts Used for Liver Transplantation and Hepato-Biliary-Pancreatic Surgery.

Journal of hepato-biliary-pancreatic sciences·2026
Same journal

Correction to "Global Trends in Perioperative Imaging Workups and Records for Hepatobiliary and Pancreatic Surgery: Reports From 103 Facilities Worldwide".

Journal of hepato-biliary-pancreatic sciences·2026
Same journal

Pure Laparoscopic Living Donor Right Hepatectomy: A Multifactorial Evolutional Learning Curve Analysis From a Single-Surgeon High-Volume Series.

Journal of hepato-biliary-pancreatic sciences·2026
Same journal

Preoperative Alcohol Consumption Before Hepatocellular Carcinoma Resection: From Prognostic Marker to Modifiable Addiction-Related Risk Factor.

Journal of hepato-biliary-pancreatic sciences·2026
Same journal

Neoadjuvant Chemotherapy (FOLFIRINOX or Gemcitabine With Nab-Paclitaxel) for Borderline-Resectable Pancreatic Cancer: Long-Term Results of a Randomized Controlled Trial (NUPAT-01).

Journal of hepato-biliary-pancreatic sciences·2026
See all related articles

Related Experiment Video

Updated: Nov 12, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.6K

Current progress in systemic therapy for biliary tract cancers.

Margaret Sutherland1, Osama Ahmed2, Adnan Zaidi2

  • 1College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.

Journal of Hepato-Biliary-Pancreatic Sciences
|March 18, 2021
PubMed
Summary
This summary is machine-generated.

Systemic therapies for biliary tract cancers (BTCs) are improving, with new targeted agents and immunotherapies showing promise. Advances in treating bile duct and gallbladder cancers offer hope for better patient outcomes.

Keywords:
biliary tract cancerchemotherapycholangiocarcinomagallbladder cancerimmunotherapysystemic therapytargeted therapy

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

803
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.7K

Related Experiment Videos

Last Updated: Nov 12, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.6K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

803
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.7K

Area of Science:

  • Oncology
  • Gastroenterology
  • Cancer Research

Background:

  • Biliary tract cancers (BTCs), including bile duct and gallbladder cancers, are often diagnosed at advanced stages with poor prognoses.
  • Recent advancements have expanded systemic therapy options for BTC patients.

Purpose of the Study:

  • To review recent advancements in systemic therapy for biliary tract cancers.
  • To summarize key clinical trial results in BTC treatment.

Main Methods:

  • Comprehensive literature search of PubMed and Google Scholar.
  • Inclusion of studies presented at major international cancer research conferences.

Main Results:

  • Adjuvant capecitabine demonstrates reduced relapse rates in early-stage BTC.
  • Combination chemotherapy remains a standard for advanced BTC, with targeted agents and immunotherapy showing promising responses based on molecular profiling.
  • Immunotherapy is increasingly relevant for BTC with deficient DNA mismatch repair or PD-L1 positivity.

Conclusions:

  • Systemic treatment options for BTC have significantly improved.
  • Future research focusing on novel targets, compounds, and predictive markers will drive personalized medicine in BTC.